AIMS/HYPOTHESIS: Diabetic nephropathy is associated with a high risk of cardiac mortality including sudden death. This is presumably related to an imbalance between sympathetic and parasympathetic tone resulting in a decreased heart rate variability (HRV). In non-diabetic patients a decreased HRV is known to be a strong predictor of cardiovascular death. Studies in non-diabetic patients have shown that beta-blockers improve HRV parameters known to reflect parasympathetic function. The aim of our study was to investigate effects of additional beta-blocker treatment on: cardiac autonomic function, blood pressure, and urine albumin excretion in ACE-inhibitortreated Type I (insulin-dependent) diabetes mellitus patients with abnormal albuminuria. METHODS: We studied the effects of 6 weeks treatment with metoprolol (100 mg once daily, zero order kinetics formulation) in 20 patients participating in a randomised, placebo controlled, double blind, crossover trial. Patients were simultaneously monitored under ambulatory conditions with 24-h Holter-monitoring, 24-h ambulatory blood pressure recording, and 24-h fractionated urine collections. Heart rate variability was assessed by four different methods; ambulatory HRV analysis was carried out by spectral and time domain analysis, and on days of investigation short-term spectral analysis and bed-side tests were carried out. RESULTS:Metoprolol treatment improved in vagal tone assessed by short-term spectral analysis. The 24-h ambulatory HRV analysis showed improvement in some parameters reflecting vagal function. A minor decrease in daytime diastolic blood pressure was shown, no alterations in diurnal variation of blood pressure or urine albumin excretion were observed. CONCLUSION/ INTERPRETATION: These preliminary findings indicate that beta-blocker treatment could improve autonomic function in Type I diabetic patients with abnormal albuminuria and an associated high risk of cardiovascular disease.
RCT Entities:
AIMS/HYPOTHESIS: Diabetic nephropathy is associated with a high risk of cardiac mortality including sudden death. This is presumably related to an imbalance between sympathetic and parasympathetic tone resulting in a decreased heart rate variability (HRV). In non-diabeticpatients a decreased HRV is known to be a strong predictor of cardiovascular death. Studies in non-diabeticpatients have shown that beta-blockers improve HRV parameters known to reflect parasympathetic function. The aim of our study was to investigate effects of additional beta-blocker treatment on: cardiac autonomic function, blood pressure, and urine albumin excretion in ACE-inhibitor treated Type I (insulin-dependent) diabetes mellituspatients with abnormal albuminuria. METHODS: We studied the effects of 6 weeks treatment with metoprolol (100 mg once daily, zero order kinetics formulation) in 20 patients participating in a randomised, placebo controlled, double blind, crossover trial. Patients were simultaneously monitored under ambulatory conditions with 24-h Holter-monitoring, 24-h ambulatory blood pressure recording, and 24-h fractionated urine collections. Heart rate variability was assessed by four different methods; ambulatory HRV analysis was carried out by spectral and time domain analysis, and on days of investigation short-term spectral analysis and bed-side tests were carried out. RESULTS:Metoprolol treatment improved in vagal tone assessed by short-term spectral analysis. The 24-h ambulatory HRV analysis showed improvement in some parameters reflecting vagal function. A minor decrease in daytime diastolic blood pressure was shown, no alterations in diurnal variation of blood pressure or urine albumin excretion were observed. CONCLUSION/ INTERPRETATION: These preliminary findings indicate that beta-blocker treatment could improve autonomic function in Type I diabeticpatients with abnormal albuminuria and an associated high risk of cardiovascular disease.
Authors: Steven Orlov; David Z I Cherney; Rodica Pop-Busui; Leif E Lovblom; Linda H Ficociello; Adam M Smiles; James H Warram; Andrzej S Krolewski; Bruce A Perkins Journal: Clin J Am Soc Nephrol Date: 2015-06-19 Impact factor: 8.237
Authors: Andreas Jeron; Tanja Kaiser; Christian Hengstenberg; Hannelore Löwel; Günter A J Riegger; Stephan Holmer Journal: Ann Noninvasive Electrocardiol Date: 2003-10 Impact factor: 1.468
Authors: Hanneke J B H Beijers; Isabel Ferreira; Bert Bravenboer; Jacqueline M Dekker; Giel Nijpels; Robert J Heine; Coen D A Stehouwer Journal: Diabetes Care Date: 2009-06-29 Impact factor: 19.112
Authors: Robert A Augustyniak; Maria Maliszewska-Scislo; Haiping Chen; John Fallucca; Noreen F Rossi Journal: Am J Physiol Regul Integr Comp Physiol Date: 2007-09-26 Impact factor: 3.619
Authors: Rodica Pop-Busui; Laurel Roberts; Subramaniam Pennathur; Mathias Kretzler; Frank C Brosius; Eva L Feldman Journal: Am J Kidney Dis Date: 2009-12-30 Impact factor: 8.860